Vesical Imaging-Reporting and Data System (VI-RADS) as a grouping imaging biomarker combined with a decision-tree mode to preoperatively predict the pathological grade of bladder cancer

Cao, B.; Li, Q.; Xu, P.; Zhang, Y.; Cai, S.; Rao, S.; Zeng, M.; Dai, Y.; Jiang, S.; Zhou, J.

doi:10.1016/j.crad.2024.01.031

Cited by 1 publication

(1 citation statement)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, we introduced a novel imaging modality, ICE-MRI, for early diagnosis of muscle-invasive bladder cancer based on tumoritropic infiltration of paramagnetic dyes [2] instead of colored dyes [74] with or without the conjugation to agents capable of targeting the metabolic programming of immune [75] and cancer cells [76]. Novel imaging modalities compatible with Vesical Imaging-Reporting and Data System (VI-RADS) and capable of predicting high-grade bladder cancer can facilitate the pre-operative shared decision making of patient and surgeon [77] and help predict the risk of BCG failure [78]. Further research and clinical trials are imperative to validate these findings and refine the treatment approaches for improved patient outcomes.…”

Section: Discussionmentioning

confidence: 99%

Enhancing Therapeutic Efficacy and Safety of Immune Checkpoint Inhibition for Bladder Cancer: A Comparative Analysis of Injectable vs. Intravesical Administration

Tyagi,

Hafron,

Kaufman

et al. 2024

IJMS

View full text Add to dashboard Cite

Bladder cancer (BC) presents a significant global health burden, characterized by high recurrence rates post-initial treatment. Gender differences in BC prevalence and response to therapy emphasize the importance of personalized treatment strategies. While Bacillus Calmette–Guérin (BCG) remains a cornerstone of BC therapy, resistance poses a challenge, necessitating alternative strategies. Immune checkpoint inhibitors (ICIs) have shown promise, yet systemic toxicity raises concern. Intravesical administration of ICIs offers a potential solution, with recent studies demonstrating the feasibility and efficacy of intravesical pembrolizumab. Although systemic toxicity remains a concern, its localized administration may mitigate adverse events. Additionally, liposomal delivery of ICIs exhibits promises in enhancing drug penetration and reducing toxicity. Novel imaging modalities compatible with Vesical Imaging-Reporting and Data System (VI-RADS) and capable of predicting high-grade bladder cancer can aid the pre-operative shared decision making of patient and surgeon. Future research should focus on refining treatment approaches, optimizing dosing regimens, and leveraging advanced imaging techniques to improve patient outcomes. In conclusion, intravesical immunotherapy presents a promising avenue for BC treatment, offering enhanced therapeutic effectiveness while minimizing systemic toxicity. Continued research efforts are essential to validate these findings and optimize intravesical immunotherapy’s role in BC management, ultimately improving patient outcomes.

show abstract